Thromoboxane A2 is an arachidonate product that causes platelet to change shape, to release their granules and to aggregate. Drugs that antagonize this pathway interfere with platelet aggregation and prolong bleeding time. Asprin at low dose is the prototype of this class of drugs. It inhibits the synthesis of thromboxane A2 by irreversible acetylation of the enzyme cyclo-oxygenase.
Therapeutic Uses:
Prophylaxis against myocardial infarction and prevention of stroke in patients at risk, e.g. those with transient ischemic attacks.
Leave a Reply